Date: _	Feb. 23 <sup>14</sup> , 20	<u> </u>					
Your N	lame: <u>Ryo Sawa</u>	da					
Manus	cript Title: Ratio	nale and Design	n of a phase II Stud	ly of Ramucirum	ab and Erlotinib in	Treatment-naïv	e Non-Small

Cell Lung Cancer Patients with EGFR mutation and Brain Metastases (SPIRAL-BRAIN study)

Manuscript number (if known): TLCR-23-109

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None	
Э	-	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<i>5 ,</i>		
8	Patents planned, issued or	XNone	
	pending		
•	5 5	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests	XNOTIE	
	illianciai iliterests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Feb. 23<sup>rd</sup>, 2023</u> Your Name: <u>Naoya Nishioka</u>

any entity (if not indicated

X\_\_None

\_X\_\_None

in item #1 above).

Consulting fees

Royalties or licenses

3

Maı	nuscript Title: Rationale and	Design of a phase II Stud	<u>y of Ramucirumab and Erlotinib in Treatment-naïve I</u>	Non-Small
<u>Cell</u>	<b>Lung Cancer Patients with E</b>	GFR mutation and Brain	Metastases (SPIRAL-BRAIN study)	
Maı	nuscript number (if known):	TLCR-23-109		
rela part to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that a ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitme If you are in doubt about whether to list a so.	
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to t		nsion, you should declare	defined broadly. For example, if your manuscript pe all relationships with manufacturers of antihyperter the manuscript.	
	em #1 below, report all sup time frame for disclosure is	-	d in this manuscript without time limit. For all other	items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initi	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone		
				$\dashv$
		Time frame: pas	st 36 months	
2	Grants or contracts from	X None		

5	Payment or honoraria for	X None	
Э	-	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<i>5 ,</i>		
8	Patents planned, issued or	XNone	
	pending		
•	5 5	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests	XNOTIE	
	illianciai iliterests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	·eb. 23 <sup>ru</sup> , 2023
Your Name	e: Young Hak Kim
Manuscrip	t Title: Rationale and Design of a phase II Study of Ramucirumab and Erlotinib in Treatment-naïve Non-Small
Cell Lung C	ancer Patients with EGFR mutation and Brain Metastases (SPIRAL-BRAIN study)
Manuscrip	t number (if known): <u>TLCR-23-109</u>
	rest of transparency, we ask you to disclose all relationships/activities/interests listed below that are the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third
	ose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive

medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None	
Э	-	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<i>5 ,</i>		
8	Patents planned, issued or	XNone	
	pending		
•	5 5	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests	XNOTIE	
	illianciai iliterests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date	e: <u>Feb. 23<sup>rd</sup>, 2023</u>			
You	r Name: <u>Fumiaki Kiyomi</u>			
Mar	nuscript Title: Rationale and	Design of a phase II Study	of Ramucirumab and Erlotinib in Treatment-naïve Non-S	mall
<u>Cell</u>	<b>Lung Cancer Patients with I</b>	<b>EGFR mutation and Brain M</b>	<u>letastases (SPIRAL-BRAIN study)</u>	
Mar	nuscript number (if known):	TLCR-23-109		
In th	ne interest of transparency,	we ask you to disclose all r	elationships/activities/interests listed below that are	
			ns any relation with for-profit or not-for-profit third	
part	ies whose interests may be	affected by the content of	the manuscript. Disclosure represents a commitment	
•	-	-	f you are in doubt about whether to list a	
	. , tionship/activity/interest, i	-	•	
	,	,		
The	following questions apply t	o the author's relationship	s/activities/interests as they relate to the current	
	nuscript only.	•	· · · · · · · · · · · · · · · · · · ·	
	<del></del>			
The	author's relationships/activ	vities/interests should be d	efined broadly. For example, if your manuscript pertains	<b>;</b>
	•		Ill relationships with manufacturers of antihypertensive	
	lication, even if that medica		· · · · · · · · · · · · · · · · · · ·	
	,			
In it	em #1 below, report all sup	port for the work reported	in this manuscript without time limit. For all other items	s.
	time frame for disclosure is	•	F	-,
		the past so months.		
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initial	planning of the work	
1	All support for the present	X None		
-	manuscript (e.g. funding			

Time frame: past 36 months

X\_None

X\_\_None

X\_\_None

provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

3

any entity (if not indicated

-	Decision to a boundarie for	V Nove	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
	Pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options		
4.2	5	V N	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	eb. 23 <sup>rd</sup> , 2023	
Your N	Junji Uchino	
Manus	Title: Rationale and Design of a phase II Study of Ramucirumab and Erlotinib in Treatment-naïve	Non-Small

Cell Lung Cancer Patients with EGFR mutation and Brain Metastases (SPIRAL-BRAIN study)

Manuscript number (if known): TLCR-23-109

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

-	Decision to a boundarie for	V Nove	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
	Pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options		
42	5	V N	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Feb. 23<sup>rd</sup>, 2023</u>

in item #1 above).

Royalties or licenses

Consulting fees

\_X\_\_None

X\_\_None

3

You	r Name: <u>Koichi Takayama</u>			
Maı	nuscript Title: Rationale and	Design of a phase II Study	y of Ramucirumab and Erlotinib in Treatment-naïve No	on-Small
<u>Cell</u>	<b>Lung Cancer Patients with E</b>	GFR mutation and Brain I	Metastases (SPIRAL-BRAIN study)	
Maı	nuscript number (if known):	TLCR-23-109		
rela part to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitmen If you are in doubt about whether to list a so.	
	following questions apply to nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the current	
to t	• •	nsion, you should declare	defined broadly. For example, if your manuscript pertal relationships with manufacturers of antihypertensible manuscript.	
	em #1 below, report all sup time frame for disclosure is		d in this manuscript without time limit. For all other it	tems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	,	
		needed)		
		Time frame: Since the initi	al planning of the work	
1	All support for the present	X None		
	manuscript (e.g., funding,			1
	provision of study materials,			-
	medical writing, article			=
	processing charges, etc.)			
	No time limit for this item.			
				-
				1
		Time frame: pas	t 36 months	
2	Grants or contracts from	X None		1
	any entity (if not indicated			1

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending	Chugai-Roche Eli Lilly and Company XNone  XNone	
	meetings and/or travel		
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	X_None	

The author receives honoraria (lecture fee) and research funds from Chugai-Roche and Eli Lilly and Company.

Please place an "X" next to the following statement to indicate your agreement: